Seffalair Spiromax


salmeterol / fluticasone propionate

This medicine is authorised for use in the European Union.


Seffalair Spiromax is a medicine used for the regular treatment of asthma in adults and adolescents above 12 years of age. It is used in patients whose disease is not adequately controlled despite treatment with a combination of a short-acting beta-2 agonist and inhaled corticosteroid. It contains the active substances salmeterol and fluticasone.

This EPAR was last updated on 23/08/2021

Authorisation details

Product details
Seffalair Spiromax
Agency product number
Active substance
  • fluticasone propionate
  • salmeterol xinafoate
International non-proprietary name (INN) or common name
  • salmeterol
  • fluticasone propionate
Therapeutic area (MeSH)
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Teva B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Swensweg 5
2031GA Haarlem
The Netherlands

Product information

15/07/2021 Seffalair Spiromax - EMEA/H/C/004881 - IB/0001

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs for obstructive airway diseases

Therapeutic indication

Seffalair Spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Assessment history

How useful was this page?

Add your rating